FDA accepts United Therapeutics’ Tyvaso application for idiopathic pulmonary fibrosis
The FDA has accepted United Therapeutics’ supplemental Tyvaso application for idiopathic pulmonary fibrosis after combined TETON data showed a 111.8 mL advantage in forced vital capacity over placebo at 52 weeks.
